Followers | 45 |
Posts | 7008 |
Boards Moderated | 0 |
Alias Born | 02/24/2004 |
Saturday, September 30, 2017 5:47:04 AM
https://www.smarteranalyst.com/2017/09/29/btig-reiterates-bullish-stance-vericel-corp-vcel-following-investor-meetings-management/
Highlights from investor meetings with Vericel management.
--------------------------------------------------------------------------------
Jason Cohen, Editor-September 29, 2017, 3:04 PM EDT
Analyst Ryan Zimmerman of equity research firm BTIG has recently hosted investor meetings with management of Vericel Corp (NASDAQ:VCEL) in San Francisco. CEO Nick Colangelo and CFO Gerard Michel spoke on a variety of topics related to Vericel’s business. Overall, Zimmerman sounds more enthusiastic about his Buy rating following the meeting. (To watch Zimmerman’s track record, click here)
In a research note to clients Zimmerman wrote, “We came away from meetings with additional color on the market opportunity, the company’s commercialization efforts, and Vericel’s regulatory focus for other assets beyond MACI (i.e. Ixmyelocel-T). Investor interest was encouraging and while shares have moved up since the last quarterly earnings call, we continue to see upside as VCEL is growing revenue faster than peers but remains at a discount on a revenue basis.”
“Mgmt. sees the opportunity for MACI among patients as ~10k-15k patients today and these estimates remain conservative, limited for younger patients with favorable commercial insurance. We believe the market may be larger. That said, from a MD standpoint, there were a core group of ~350 users of Carticel previously (although up to 1,000 may send in biopsies), mgmt. sees the potential MD opportunity as ~3,000 who could potentially add MACI to their practice,” the analyst added.
Furthermore, “Investors were interested to hear about Ixmyelocel-T, as a potential catalyst for shares may be near-term. Mgmt. has remained constrained on discussion of the non-core asset so as not to get ahead of themselves but Vericel expects to meet with the FDA before the end of the 3rd quarter.
Shares of Vericel are rising nearly 8% to $6.07 as of 2:59PM EDT.
VCEL
Recent VCEL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 08:06:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/02/2024 08:54:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 08:06:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/01/2024 05:16:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/20/2024 08:05:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:10:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:05:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:16:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:55:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:06:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 08:05:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/04/2024 02:25:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 05:27:28 PM
- Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024 • GlobeNewswire Inc. • 08/29/2024 01:17:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 12:03:45 PM
- Vericel Announces FDA Approval and Commercial Availability of MACI Arthro • GlobeNewswire Inc. • 08/26/2024 11:45:47 AM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 08/16/2024 08:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 08:05:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 09:03:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:08:47 PM
- Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns • GlobeNewswire Inc. • 08/15/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:17:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:05:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:11:15 PM
- Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 12:30:00 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM